Friday, July 31
Drug trial failures hammer two pharma giants in one day
Novo Nordisk and Moderna both stumbled on late-stage clinical results Friday, reminding the market how much of their value rests on bets that haven't paid off yet.
Top Stories
Novo Nordisk's pipeline problem is now too big to hide behind Wegovy
Novo Nordisk shares cratered nearly 9% Friday after its experimental heart drug ziltivekimab failed to show meaningful risk reduction in a major Phase 3 trial, erasing more than $30 billion in market value in a single session.
The company has leaned heavily on its weight-loss franchise to carry its valuation, but with Eli Lilly pressing hard on that same turf, a failed diversification attempt at this scale signals that the backup plan is not ready.
Chevron's blowout quarter shows who actually wins when oil prices spike
Chevron reported its highest quarterly profit in at least six years on Friday, beating expectations as surging energy prices tied to the Iran conflict and Strait of Hormuz closure drove upstream output and refining margins to exceptional levels.
Combined with ExxonMobil posting a four-year profit high in the same week, the results confirm that geopolitical disruption in oil supply routes translates almost directly into windfall earnings for the majors.
AbbVie and Moderna both beat the quarter, then got punished for what comes next
AbbVie topped earnings estimates on strong drug sales but cut its full-year profit guidance to absorb a pending acquisition, while Moderna narrowed its losses and beat revenue targets yet sold off sharply after its norovirus vaccine study missed early success benchmarks.
The pattern across both companies is the same: a good quarter buys no goodwill when the forward guidance or pipeline news gives the market a reason to sell.
Also Today
- Stellantis recalling 1.5 million Ram trucks over seat belt safety flaw
- Colgate beat estimates but cautious outlook spooked buyers
- Becton Dickinson recalls needle sets over reported use failures
Takeaway
Friday's session was defined by the gap between what companies delivered and what the market needed to hear next, with pipeline failures and guidance cuts doing more damage than strong quarterly numbers could repair.
The most concrete thing to watch early next week is whether Novo Nordisk's management offers any credible path forward beyond its weight-loss drugs, since the market just repriced the entire diversification story in a single afternoon.
